RNA polymerase - An important molecular target of triptolide in cancer cells

Cancer Letters

Volumn 292, Issue 2, 2010, Pages 149-152

  Pan, Jingxuan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cancer; Molecular target; RNA polymerase; Triptolide

Indexed keywords

RNA POLYMERASE; TRIPTOLIDE; DITERPENE; DNA DIRECTED RNA POLYMERASE; EPOXIDE; PHENANTHRENE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; GENE TARGETING; HUMAN; IC 50; IMMUNOMODULATION; PRIORITY JOURNAL; SHORT SURVEY; TRANSCRIPTION REGULATION; ANIMAL; CELL DIVISION; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASM; ONCOGENE; PATHOLOGY; REVIEW;

TRIPTERYGIUM WILFORDII;

ANIMALS; CELL DIVISION; DITERPENES; DNA-DIRECTED RNA POLYMERASES; EPOXY COMPOUNDS; HUMANS; NEOPLASMS; ONCOGENES; PHENANTHRENES;

EID: 77951932747     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.11.018     Document Type: Review

References (44)

1. Corson T.W., Crews C.M. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 2007, 130:769-774.
2. Tao X.L., Sun Y., Dong Y., Xiao Y.L., Hu D.W., Shi Y.P., Zhu Q.L., Dai H., Zhang N.Z. A prospective, controlled, double-blind, cross-over study of Tripterygium wilfodii Hook. f. in treatment of rheumatoid arthritis. Chin. Med. J. (Engl) 1989, 102:327-332.
3. Jiang X. Clinical observations on the use of the Chinese herb Tripterygium wilfordii Hook. for the treatment of nephrotic syndrome. Pediatr. Nephrol. 1994, 8:343-344.
4. Efferth T., Li P.C., Konkimalla V.S., Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol. Med. 2007, 13:353-361.
5. Tao X., Schulze-Koops H., Ma L., Cai J., Mao Y., Lipsky P.E. Effects of Tripterygium wilfordii hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis Rheum. 1998, 41:130-138.
6. Kupchan S.M., Court W.A., Dailey R.G., Gilmore C.J., Bryan R.F. Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J. Am. Chem. Soc. 1972, 94:7194-7195.
7. Shi X., Jin Y., Cheng C., Zhang H., Zou W., Zheng Q., Lu Z., Chen Q., Lai Y., Pan J. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin. Cancer Res. 2009, 15:1686-1697.
8. Vispe S., DeVries L., Creancier L., Besse J., Breand S., Hobson D.J., Svejstrup J.Q., Annereau J.P., Cussac D., Dumontet C., Guilbaud N., Barret J.M., Bailly C. Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol. Cancer Ther. 2009, 8:2780-2790.
9. Li Z., Zhou Z.L., Miao Z.H., Lin L.P., Feng H.J., Tong L.J., Ding J., Li Y.C. Design and synthesis of Novel C14-Hydroxyl substituted triptolide derivatives as potential selective antitumor agents. J. Med. Chem. 2009.
10. Chan E.W., Cheng S.C., Sin F.W., Xie Y. Triptolide induced cytotoxic effects on human promyelocytic leukemia, T cell lymphoma and human hepatocellular carcinoma cell lines. Toxicol. Lett. 2001, 122:81-87.
11. Q. Chen, Z. Lu, Y. Jin, Y. Wu, and J. Pan, Triptolide inhibits Jak2 transcription and induces apoptosis in human myeloproliferative disorder cells bearing Jak2V617F through caspase-3-mediated cleavage of Mcl-1, Cancer Lett., in press, doi:10.1016/j.canlet.2009.10.019.
12. Carter B.Z., Mak D.H., Schober W.D., McQueen T., Harris D., Estrov Z., Evans R.L., Andreeff M. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006, 108:630-637.
13. Zhang C., Cui G.H., Liu F., Wu Q.L., Chen Y. Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro. Acta Pharmacol. Sin. 2006, 27:1438-1446.
14. Yinjun L., Jie J., Yungui W. Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. Leuk. Res. 2005, 29:99-105.
15. Aoyagi Y., Hitotsuyanagi Y., Hasuda T., Matsuyama S., Fukaya H., Takeya K., Aiyama R., Matsuzaki T., Hashimoto S. Fluorination of triptolide and its analogues and their cytotoxicity. Bioorg. Med. Chem. Lett. 2008, 18:2459-2463.
16. Chen Y.W., Lin G.J., Chia W.T., Lin C.K., Chuang Y.P., Sytwu H.K. Triptolide exerts anti-tumor effect on oral cancer and KB cells in vitro and in vivo. Oral. Oncol. 2009, 45:562-568.
17. Lee K.Y., Chang W., Qiu D., Kao P.N., Rosen G.D. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J. Biol. Chem. 1999, 274:13451-13455.
18. Frese S., Pirnia F., Miescher D., Krajewski S., Borner M.M., Reed J.C., Schmid R.A. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 2003, 22:5427-5435.
19. Kiviharju T.M., Lecane P.S., Sellers R.G., Peehl D.M. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin. Cancer Res. 2002, 8:2666-2674.
20. Yang S., Chen J., Guo Z., Xu X.M., Wang L., Pei X.F., Yang J., Underhill C.B., Zhang L. Triptolide inhibits the growth and metastasis of solid tumors. Mol. Cancer Ther. 2003, 2:65-72.
21. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749-759.
22. Qiu D., Kao P.N. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs 2003, 4:1-18.
23. Du Z.Y., Li X.Y., Li Y.C., Wang S.Y. Analysis of triptolide-regulated gene expression in Jurkat cells by complementary DNA microarray. Acta Pharmacol. Sin. 2003, 24:864-872.
24. Jin Y., Chen Q., Lu Z., Chen B., Pan J. Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome. Cancer Sci. 2009, 100:2210-2217.
25. Jin Y., Chen Q., Shi X., Lu Z., Cheng C., Lai Y., Zheng Q., Pan J. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci. 2009, 100:1335-1343.
26. Wan C.K., Wang C., Cheung H.Y., Yang M., Fong W.F. Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in p53-deficient HL-60 cells. Cancer Lett. 2006, 241:31-41.
27. Phillips P.A., Dudeja V., McCarroll J.A., Borja-Cacho D., Dawra R.K., Grizzle W.E., Vickers S.M., Saluja A.K. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 2007, 67:9407-9416.
28. McCallum C., Kwon S., Leavitt P., Shen D.M., Liu W., Gurnett A. Triptolide binds covalently to a 90kDa nuclear protein. Role of epoxides in binding and activity. Immunobiology 2007, 212:549-556.
29. Leuenroth S.J., Crews C.M. Triptolide-induced transcriptional arrest is associated with changes in nuclear substructure. Cancer Res. 2008, 68:5257-5266.
30. Jonkers J., Berns A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell 2004, 6:535-538.
31. Baselga J., Arribas J. Treating cancer's kinase 'addiction'. Nat. Med. 2004, 10:786-787.
32. Chen R., Gandhi V., Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006, 66:10959-10966.
33. Clohessy J.G., Zhuang J., Brady H.J. Characterisation of Mcl-1 cleavage during apoptosis of haematopoietic cells. Brit. J. Haematol. 2004, 125:655-665.
34. Sharma S.V., Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007, 21:3214-3231.
35. Felsher D.W. Tumor dormancy and oncogene addiction. APMIS 2008, 116:629-637.
36. Melo J.V., Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 2007, 7:441-453.
37. Quintas-Cardama A., Kantarjian H., Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat. Rev. Drug Discov. 2007, 6:834-848.
38. Dewaele B., Wasag B., Cools J., Sciot R., Prenen H., Vandenberghe P., Wozniak A., Schoffski P., Marynen P., Debiec-Rychter M. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin. Cancer Res. 2008, 14:5749-5758.
39. Fumo G., Akin C., Metcalfe D.D., Neckers L. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004, 103:1078-1084.
40. Sambol E.B., Ambrosini G., Geha R.C., Kennealey P.T., Decarolis P., O'Connor R., Wu Y.V., Motwani M., Chen J.H., Schwartz G.K., Singer S. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res. 2006, 66:5858-5866.
41. Ishihara K., Kaneko M., Kitamura H., Takahashi A., Hong J.J., Seyama T., Iida K., Wada H., Hirasawa N., Ohuchi K. Mechanism for the decrease in the FIP1L1-PDGFRalpha protein level in EoL-1 cells by histone deacetylase inhibitors. Int. Arch. Allergy Immunol. 2008, 146(Suppl. 1):7-10.
42. Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., Moscinski L., Smith C., Wu J., Jove R., Atadja P., Bhalla K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003, 63:5126-5135.
43. Matei D., Satpathy M., Cao L., Lai Y.C., Nakshatri H., Donner D.B. The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. J. Biol. Chem. 2007, 282:445-453.
44. Mak D.H., Schober W.D., Chen W., Konopleva M., Cortes J., Kantarjian H.M., Andreeff M., Carter B.Z. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol. Cancer Ther. 2009, 8:2509-2516.